Cocrystal Pharma, Inc. (NASDAQ:COCP)’s traded shares stood at 1,494,978 during the latest session, with the company’s beta value hitting 0.75. At the last check today, the stock’s price was $1.23, to imply an increase of 0.84% or $0.01 in intraday trading. The COCP share’s 52-week high remains $3.46, putting it -181.3% down since that peak but still an impressive +38.21% since price per share fell to its 52-week low of $0.76. The company has a valuation of $120.86 Million, with an average of 3.32 Million shares in intraday trading volume over the past 10 days and average of 15.38 Million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cocrystal Pharma, Inc. (COCP), translating to a mean rating of 2. Of 3 analyst(s) looking at the stock, none analyst(s) give COCP a Sell rating. None of those analysts rate the stock as Overweight while no one advise Hold as 3 recommend it as a Buy. None analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.04.
After registering a 0.84% upside in the latest session, Cocrystal Pharma, Inc. (COCP) has traded green over the past five days. The stock hit a weekly high of $1.25 this Friday, Jun 04, jumping 1.6% in its intraday price action. The 5-day price performance for the stock is 7.89%, and -42.52% over 30 days. With these gigs, the year-to-date price performance is -9.56%. Short interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) saw shorts transact 2.93 Million shares and set a 0.19 days time to cover.
Analysts on Wall Street suggest a consensus price target of $4.5, implying an increase of 265.85% to the stock’s recent value. The extremes give us $4 and $5 for target low and target high price respectively. As such, COCP has been trading 306.5% off suggested target high and 225.2% from its likely low.
Cocrystal Pharma, Inc. (COCP) estimates and forecasts
Looking at statistics comparing Cocrystal Pharma, Inc. share performance against respective industry, we note that the company has outperformed competitors. Cocrystal Pharma, Inc. (COCP) shares are -26.06% down over the last 6 months, with its year-to-date growth rate higher than industry average at 11.76% against 9%. But the analysts are intensifying their growth estimates for the 2021 fiscal year. Revenue is forecast to grow 42.9% this quarter before jumping 20% for the next one. The rating firms project that company’s revenue will grow 9.2% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is $550Million. Meanwhile, for the quarter ending September 01, 2021, a total of 1 analyst(s) estimate revenue growth to $550Million. Earnings reports from the last fiscal year show that sales brought in $554Million and $560Million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to dip -0.7% before falling -1.8% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 40.7% for the past 5-year period. While 2021 is set for a 88.4% return in earnings, projections for the next 5 years are at 0% annually.
Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.
Add them to your watchlist before they take off!
Cocrystal Pharma, Inc. (NASDAQ:COCP)’s Major holders
Cocrystal Pharma, Inc. insiders hold 17.84% of total outstanding shares, with institutional holders owning 26.68% of the shares at 32.47% float percentage. In total, 38 institutions holds shares in the company, led by Renaissance Technologies, LLC. As of Mar 30, 2021, the company held over 4.25 Million shares (or 14.22% of shares), all amounting to roughly $5.91 Million.
The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 1.96 Million shares, or about 6.54% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $2.72 Million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Cocrystal Pharma, Inc. (COCP) shares. Going by data provided on Mar 30, 2021, Vanguard Total Stock Market Index Fund holds roughly 1,201,742 shares. This is just over 4.02% of the total shares, with a market valuation of $1.67 Million. Data from the same date shows that the other fund manager holds a little less at 663.62 Thousand, or 2.22% of the shares, all valued at about $922.44 Thousand.